Skip to content

Oncoinvent ASA Sustainability Reports

Oncoinvent ASA is a clinical-stage radiopharmaceutical company developing innovative alpha-emitting therapeutics for solid cancers. Its lead product candidate, Radspherin, targets metastatic cancers within the abdominal cavity.

Sector: Professional & technical services

Country: Norway

Exchange: Oslo Børs

ISIN: NO0013711713

18 reports from 2015 to 2024